Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, ...

Wave’s FDA clearance of MeRT® for PTSD marks an important advancement for patients whose lives have been shaped by ...

Prof Tim Denison, Royal Academy of Engineering Chair in Emerging Technologies and co-founder of Amber Therapeutics, explores ...

ReShape Lifesciences® announced the granting of an international patent for its Diabetes Neuromodulation technology from the Australian Patent Office, providing protection until April 12, 2039. This ...

ReShape Lifesciences announced the granting of an international patent for its Diabetes Neuromodulation technology, which combines proprietary vagus nerve modulation with vagal stimulation aimed at ...

The R&D on neuromodulation technology for the treatment and management of metabolic syndrome conducted by a team led by Dr. Ki-young Shin of Human Care Electro-Medical Device Research Center, ...

Sonomind SAS raised €20 million (US$23 million) in a series A funding round for its ultrasound-based neuromodulation technology for depression. The funds will be used for clinical trials of the ...

TAMPA, Fla. & NETANYA, Israel--(BUSINESS WIRE)--Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system.

Magnus Medical, Inc., a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, today announced it received 510(k) clearance from the U.S.

The sleep supplement market is full of products that work on the margins. Melatonin, magnesium, ashwagandha. They all have ...

Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across ...